Latest Hotspot

Hanmi collaborates clinically and signs supply deal with MSD to test BH3120 along with KEYTRUDA® (pembrolizumab)

26 April 2024
3 min read

Hanmi Pharmaceutical, a prominent Korean biopharma corporation that concentrates on notable research fields, including oncology, obesity/metabolism, and rare disorders, has declared the formation of a Clinical Trial Collaboration and Supply Agreement with MSD.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Following the signing of the agreement, Hanmi Pharmaceutical is set to initiate a phase 1 clinical trial to test the safety and efficacy of its cancer immunotherapy agent, ‘BH3120’, used together with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This trial will focus on patients suffering from progressive or metastatic solid tumors. Hanmi Pharmaceutical will be the trial sponsor while MSD will provide KEYTRUDA.

The investigational drug ‘BH3120’ incorporates 'Pentambody', an advanced bispecific antibody technology, currently being co-developed by Hanmi Pharmaceutical and its subsidiary in China, BJHM.

Pentambody technology uniquely links one antibody to two different targets at the same time, which enhances the performance in both cancer immunotherapy and targeted therapy. Specifically, BH3120 functions as an IgG-like bivalent bispecific antibody, primarily targeting PD-L1 and 4-1BB, displaying a preference in binding affinity for PD-L1.

Other existing antibody therapies targeting 4-1BB often encounter issues with safety. However, diverse non-clinical trials have demonstrated that BH3120 can distinctly separate immune responses in the tumor microenvironment (TME) from those in normal tissues, highlighting its potential as both an effective and safe treatment for cancer.

Dr. Kim Dong-wan, who leads the Clinical Trials Center at Seoul National University Hospital, serves as the Principal Investigator for the phase 1 trial of BH3120 in both Korea and the US. He commented on the collaboration with MSD, saying, "With our joint efforts on BH3120 alongside KEYTRUDA, we aim to enhance treatment results for patients facing relapsed or refractory diseases."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of April 25, 2024, there are 26 investigational drugs for the 4-1BB and PDL1 target, including 44 indications, 35 R&D institutions involved, with related clinical trials reaching 74, and as many as 9787 patents.

BH-3120 targets both 4-1BB and PDL1 and is being developed for the treatment of solid tumors. Currently in Phase 1, BH-3120 is undergoing early-stage clinical trials to assess its safety and efficacy.

图形用户界面, 文本, 应用程序

描述已自动生成

BeiGene Secures EC Nod for Tislelizumab in Treating Non-Small Cell Lung Cancer
Latest Hotspot
3 min read
BeiGene Secures EC Nod for Tislelizumab in Treating Non-Small Cell Lung Cancer
26 April 2024
BeiGene, Ltd. disclosed that tislelizumab has received approval from the European Commission for use in treating non-small cell lung cancer.
Read →
Initial Dosing in Phase I Glioblastoma Trial by ITM, Helmholtz Munich, and University Hospital Münster
Latest Hotspot
3 min read
Initial Dosing in Phase I Glioblastoma Trial by ITM, Helmholtz Munich, and University Hospital Münster
25 April 2024
ITM, Helmholtz Munich, and University Hospital Münster Report Initial Dosing of First Participant in Phase I Research Trial for Glioblastoma.
Read →
Progress in the Research of Therapeutic Peptides Targeting GPCRs
Hot Spotlight
10 min read
Progress in the Research of Therapeutic Peptides Targeting GPCRs
25 April 2024
GPCRs, as key signal transduction molecules on the cell surface, regulate various physiological processes and constitute one-third of the targets for clinical drug applications.
Read →
EU Sanctions Voydeya as Supplementary Treatment for PNH with Persistent Haemolytic Anaemia
Latest Hotspot
3 min read
EU Sanctions Voydeya as Supplementary Treatment for PNH with Persistent Haemolytic Anaemia
25 April 2024
Voydeya has been sanctioned in the EU as a supplementary treatment alongside ravulizumab or eculizumab for adults with PNH who still suffer from persistent haemolytic anaemia.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.